CAR-T Therapy for Autoimmune Disease: FDA IND Clearance
- The Food and Drug Administration has given the green light to Calibr-Skaggs Institute for Innovative Medicines to begin clinical trials for its switchable chimeric antigen receptor T cell...
- the phase 1 clinical trial will assess the safety and effectiveness of this novel sCAR-T therapy in individuals with myositis, systemic sclerosis, lupus, and rheumatoid arthritis.
- Autoimmune diseases, frequently enough chronic, affect approximately 15 million people in the U.S. and up to 12% of the global population.
The FDA has approved clinical trials for a novel sCAR-T therapy, a significant step forward in treating autoimmune diseases. Calibr-Skaggs’ CLBR001 + SWI019 aims to revolutionize treatment by eliminating the need for lymphodepletion, an frequently enough-debilitating chemotherapy procedure. This innovative CAR-T therapy targets conditions like lupus, rheumatoid arthritis, and myositis, perhaps transforming the treatment landscape for millions. this investigational new drug (IND) offers hope by reducing side effects commonly associated with conventional CAR-T approaches and improving patient outcomes. This trial could broaden the use of sCAR-T therapy. News Directory 3 is following the latest developments closely. Discover whatS next in autoimmune disease treatment.
FDA approves Calibr-Skaggs sCAR-T Therapy Trial for Autoimmune Diseases
Updated June 26, 2025
The Food and Drug Administration has given the green light to Calibr-Skaggs Institute for Innovative Medicines to begin clinical trials for its switchable chimeric antigen receptor T cell (sCAR-T) therapy, known as CLBR001 + SWI019. This new investigational drug application (IND) will focus on treating patients suffering from various autoimmune conditions. Patient recruitment for the phase 1 trial (NCT06913608) is expected to start soon.
the phase 1 clinical trial will assess the safety and effectiveness of this novel sCAR-T therapy in individuals with myositis, systemic sclerosis, lupus, and rheumatoid arthritis. Future expansion to other autoimmune indications is possible. The sCAR-T therapy is designed to minimize the side effects and patient burden typically associated with lymphodepletion, a pre-treatment often required for traditional CAR-T approaches. This is a notable concern for both rheumatologists and their patients.
Autoimmune diseases, frequently enough chronic, affect approximately 15 million people in the U.S. and up to 12% of the global population. CAR-T cell therapy has shown promise in treating certain autoimmune diseases by essentially “resetting” the immune system, improving patients’ quality of life, and reducing their reliance on lifelong immunosuppressants. However, standard CAR-T cell therapies necessitate lymphodepletion, a chemotherapy procedure that eliminates existing immune cells to facilitate the expansion of CAR-T cells. This process can increase the risk of infection and other severe side effects. CLBR001 + SWI019 aims to circumvent these issues by removing the need for lymphodepletion, thereby reducing side effects and possibly broadening treatment accessibility.
“Patients with chronic autoimmune diseases need curative options that do not require life-long immunosuppressive therapy to manage their condition,” said Travis Young, vice president of biologics at Calibr-Skaggs. “Our CLBR001 + SWI019 cell therapy has the potential to transform the treatment paradigm for patients by eliminating chemotherapy-associated risks.”
Chan Beals, chief medical officer at Calibr-Skaggs, emphasized the potential impact of the therapy. “Successfully establishing safety and efficacy of CLBR001 + SWI019 for conditions like lupus and rheumatoid arthritis could pave the way for broader therapeutic use in other autoimmune diseases, offering new hope to many more patients in the future,” Beals said.
What’s next
With patient enrollment anticipated to begin shortly, the trial’s progress will be closely watched by the medical community and those affected by autoimmune disorders.The innovative approach of this switchable CAR-T therapy offers a potential new avenue for treatment, addressing the limitations of current methods.